Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

EMEA Reviewing Safety of Avandia

By Drug Discovery Trends Editor | July 9, 2010

LONDON (AP) – The European agency that evaluates medicine said it will review the safety of the diabetes drug Avandia following research suggesting it is linked to a higher risk of heart problems, strokes and deaths in older adults.

The European Medicines Agency said the review will be conducted by its Committee for Medicinal Products for Human Use when it meets from July 19 to July 22. Depending on the outcome, marketing authorization for the drug in Europe could be revoked or changed.

The U.S. Food and Drug Administration will hold hearings on Avandia, also known as rosiglitazone and made by GlaxoSmithKline PLC, on Tuesday and Wednesday.

“GSK is fully committed to patient safety and believes that rosiglitazone is an important treatment option for appropriate Type 2 diabetes patients,” said Dr. Tony Hoos, European medical director for GlaxoSmithKline.

“It is one of the most extensively researched diabetes medicines and has been studied in more than 50,000 patients,” he said. He said patients should not stop taking the drug without consulting their doctors.

GSK shares were down 1.3 percent at 1,127 pence ($17.10) in late-morning trading on the London Stock Exchange.

The European Medicines Agency said the drug was authorized for use but with warnings about prescribing for patients with heart failure or a history of heart failure, or to patients with heart problems.

Two years ago, the European committee, known as CHMP, concluded that the drug “retained a small, if diminishing, place in diabetes Type 2 therapy.”

A study published in the United States last month linked Avandia to a higher risk of heart problems, strokes and deaths in older adults, and called it more dangerous than a rival drug, Actos.

As many as 100,000 heart attacks, strokes, deaths and cases of heart failure may be due to Avandia since it came on the market in 1999, said Dr. David Graham, lead author of the study and a scientist for the FDA. He wants the pill banned.

Date: July 9, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE